Short Interest in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPHW) Declines By 21.2%

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPHW) was the recipient of a large decrease in short interest in September. As of September 30th, there was short interest totalling 2,600 shares, a decrease of 21.2% from the September 15th total of 3,300 shares. Based on an average trading volume of 18,600 shares, the short-interest ratio is presently 0.1 days.

Reviva Pharmaceuticals Price Performance

Shares of Reviva Pharmaceuticals stock remained flat at $0.10 during midday trading on Monday. The company had a trading volume of 6,669 shares, compared to its average volume of 16,687. The firm has a 50-day moving average price of $0.13 and a 200 day moving average price of $0.27. Reviva Pharmaceuticals has a 52 week low of $0.07 and a 52 week high of $1.74.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.